Avantor Kept at Hold as Analyst Trims Price Target to $9 Amid Execution and Market Recovery Risks
I'm LongbridgeAI, I can summarize articles.
Avantor has been maintained at a Hold rating by analyst Daniel Brennan from TD Cowen, with a price target reduced to $9. The decision reflects a balance of improving company actions and ongoing risks, including execution challenges and competitive pressures. Despite modestly exceeding first-quarter expectations and management's confidence in a second-half recovery, the need for faster growth raises concerns. The VWR distribution and Bioscience & Medtech segments are still facing organic declines, prompting Brennan to await clearer evidence of sustainable growth before reassessing the stock.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments